Bacterial Conjunctivitis Clinical Trial
Official title:
A Randomized, Multicenter, Double-Masked, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Vancomycin Hydrochloride Ophthalmic Ointment 1.1% in Patients With Moderate to Severe Bacterial Conjunctivitis
This is a Phase 3 study to evaluate the safety and efficacy of a vancomycin hydrochloride ophthalmic ointment dosed 4 times daily for 7 days compared to placebo (vehicle) in patients with moderate to severed Gram-positive bacterial conjunctivitis.
Bacterial conjunctivitis is common ocular disease caused by various types of bacteria
including methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant
Staphylococcus epidermidis (MRSE). External ocular infections such as those caused by MRSA or
MRSE frequently are not serious but in rare cases may be severe enough to threaten vision.
When ocular infections due to resistant organisms such as MRSA/MRSE do not respond to empiric
treatment with approved antibiotics, there are few treatment options. Vancomycin is one of
the few treatment options that has been shown to be effective against all clinical isolates
of MRSA/MRSE.
This study is a Phase 3 study to evaluate the safety and efficacy of a vancomycin
hydrochloride ophthalmic ointment in patients with moderate to severed Gram-positive
bacterial conjunctivitis including those with MRSA and MRSE. Subjects, who are adenovirus
negative, will be dosed with vancomycin hydrochloride ophthalmic ointment or placebo
(vehicle) 4 times daily for 7 days and evaluated for clinical and bacterial resolution of
their infection along with an assessment of the safety of the investigational product.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00565123 -
Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day for Bacterial Conjunctivitis
|
Phase 2/Phase 3 | |
Completed |
NCT00972777 -
Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis
|
Phase 2/Phase 3 | |
Completed |
NCT00798577 -
Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment
|
Phase 4 | |
Completed |
NCT00759148 -
Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis
|
Phase 3 | |
Completed |
NCT00331916 -
AL-15469A for the Treatment of Bacterial Conjunctivitis
|
Phase 3 | |
Completed |
NCT01573910 -
An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients
|
Phase 3 | |
Terminated |
NCT01330355 -
Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis
|
Phase 3 | |
Completed |
NCT00332293 -
AL-15469A for the Treatment of Bacterial Conjunctivitis
|
Phase 3 | |
Completed |
NCT03004924 -
Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo
|
Phase 3 | |
Completed |
NCT02980523 -
Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)
|
Phase 2 | |
Completed |
NCT01877694 -
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
|
Phase 2 | |
Completed |
NCT01175590 -
Safety of Besivanceā¢ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle
|
Phase 3 | |
Completed |
NCT00464438 -
A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis
|
Phase 4 | |
Completed |
NCT00312338 -
Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora
|
Phase 4 | |
Recruiting |
NCT03235141 -
Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00105469 -
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)
|
Phase 3 | |
Completed |
NCT00105534 -
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)
|
Phase 3 | |
Recruiting |
NCT06363292 -
Study to Evaluate the Safety and Tolerability of PRO-231 Ophthalmic Solution Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects.
|
Phase 1 | |
Withdrawn |
NCT01238783 -
Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis
|
Phase 2 | |
Terminated |
NCT01740388 -
Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis
|
Phase 3 |